<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02610439</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2013-02292</org_study_id>
    <secondary_id>NCI-2013-02292</secondary_id>
    <secondary_id>ECOG-E5103T4</secondary_id>
    <secondary_id>E5103T4</secondary_id>
    <secondary_id>E5103T4</secondary_id>
    <secondary_id>U10CA180820</secondary_id>
    <nct_id>NCT02610439</nct_id>
  </id_info>
  <brief_title>Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Peripheral Neuropathy Receiving Paclitaxel for Breast Cancer</brief_title>
  <official_title>Exploratory Next Generation Sequencing to Identify Causative Variants for Taxane-Induced Peripheral Neuropathy From Breast Cancer Study E5103 Germline DNA Samples</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This research trial studies whole exome sequencing in finding causative variants in germline&#xD;
      deoxyribonucleic acid (DNA) samples from patients with peripheral neuropathy receiving&#xD;
      chemotherapy for breast cancer. Studying samples of germline DNA in the laboratory from&#xD;
      patients with peripheral neuropathy receiving paclitaxel for breast cancer may help doctors&#xD;
      learn more about changes that occur in DNA and identify biomarkers related to peripheral&#xD;
      neuropathy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To identify, using next generation sequencing, rare variants of large effect size that&#xD;
      impact the risk of peripheral neuropathy in patients of African and European descent in the&#xD;
      clinical trial ECOG-5103 (E5103).&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Previously collected germline DNA samples are analyzed via whole exome sequencing.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 25, 2014</start_date>
  <completion_date type="Anticipated">January 1, 2100</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2100</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Identification of rare coding variants of large effect that predict the risk of peripheral neuropathy</measure>
    <time_frame>Baseline</time_frame>
    <description>Assess by Burden analysis.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">575</enrollment>
  <condition>Breast Carcinoma</condition>
  <condition>Neuropathy</condition>
  <arm_group>
    <arm_group_label>Ancillary-Correlative (whole exome sequencing)</arm_group_label>
    <description>Previously collected germline DNA samples are analyzed via whole exome sequencing.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Ancillary-Correlative (whole exome sequencing)</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with breast cancer enrolled on E5103 with or without peripheral neuropathy.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  European American patients with DNA available and designated case or control&#xD;
&#xD;
          -  African American patients with DNA available and designated case or control status&#xD;
&#xD;
          -  Patients who developed grade 2-4 for African American (AA) and grade 3-4 for European&#xD;
             American (EA) peripheral neuropathy during their treatment with paclitaxel and who did&#xD;
             not develop peripheral neuropathy following a full course of treatment with paclitaxel&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bryan P Schneider</last_name>
    <role>Principal Investigator</role>
    <affiliation>Eastern Cooperative Oncology Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Eastern Cooperative Oncology Group</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bryan P. Schneider</last_name>
      <phone>317-274-6473</phone>
      <email>bpschnei@iupui.edu</email>
    </contact>
    <investigator>
      <last_name>Bryan P. Schneider</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>November 19, 2015</study_first_submitted>
  <study_first_submitted_qc>November 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 20, 2015</study_first_posted>
  <last_update_submitted>October 1, 2021</last_update_submitted>
  <last_update_submitted_qc>October 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

